A Phase II Study of Induction Therapy with Carboplatin and Gemcitabine among Patients with Locally Advanced Non-small Cell Lung Cancer
Autor: | Henk C. Hoogsteden, R. J. van Klaveren, V. Surmont, René M. Vernhout, K. Y. Tan, Suresh Senan, G. van Wijhe, Joachim G.J.V. Aerts, J. Van Meerbeeck, G.T. Verhoeven |
---|---|
Přispěvatelé: | Radiation Oncology |
Rok vydání: | 2006 |
Předmět: |
Oncology
Pulmonary and Respiratory Medicine Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Locally advanced NSCLC Phases of clinical research Neutropenia medicine.disease Gemcitabine Carboplatin Induction Regimen chemistry.chemical_compound chemistry Internal medicine medicine Lung cancer business Febrile neutropenia medicine.drug |
Zdroj: | Journal of Thoracic Oncology, 1(6), 532-536. International Association for the Study of Lung Cancer Aerts, J G J V, Surmont, V, Van Klaveren, R J, Tan, K Y, Senan, S, Van Wijhe, G, Vernhout, R, Verhoeven, G T, Hoogsteden, H C & Van Meerbeeck, J P 2006, ' A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer ', Journal of Thoracic Oncology, vol. 1, no. 6, pp. 532-536 . https://doi.org/10.1097/01243894-200607000-00006 |
ISSN: | 1556-0864 |
DOI: | 10.1097/01243894-200607000-00006 |
Popis: | INTRODUCTION: The objectives of this trial were to evaluate the activity and safety of gemcitabine carboplatin as induction therapy in patients with locally advanced non-small cell lung cancer METHODS: Patients received two cycles of gemcitabine (1250 mg/m on day 1 and 8), plus carboplatin (area under the curve = 5 on day 1), after which response was established. Patients received a third course only in the case of an objective response (OR). Non-responding patients were directly irradiated. Toxicity was assessed according to the NCI-CTC version 2, radiation toxicity was assessed according to RTOG criteria. Response evaluation was performed according to RECIST criteria. RESULTS: We identified 42 patients, of whom 37 were eligible. Of these, 51% (95% CI, 34%-68%) achieved an OR, all partial responses. No disease progression on therapy was established. Toxicity was mostly hematological: 35% trombocytopenia grade 3 and 4, and 40% neutropenia grade 3 and 4. No severe bleeding or hospitalization because of febrile neutropenia occurred. CONCLUSIONS: Gemcitabine and carboplatin administered according to a 3-week schedule is an active and safe induction regimen. Pending the results of a phase III study, we believe that it is a reasonable alternative among patients for whom cisplatin-based chemotherapy is contraindicated. |
Databáze: | OpenAIRE |
Externí odkaz: |